SeqOne Genomics announces Portuguese distribution partnership

SeqOne has appointed ILC Instrumentos de Laboratório to distribute its genomic analysis software platform in Portugal, and to accelerate the availability of its advanced genomic analysis solutions.

Montpellier, France – Lisboa, Portugal – September 30th 2022 – SeqOne Genomics, provider of next-generation genomic analysis solutions for personalized medicine is proud to announce a new strategic partnership with  ILC Instrumentos de Laboratório Científicos to facilitate access to its genomic analysis solutions in Portugal.  Through this partnership, ILC Instrumentos de Laboratório Científicos has been appointed as a value added distributor in Portugal.

Nicolas Philippe, CEO co-founder of SeqOne Genomics, said “We were impressed with the capabilities of ILC to provide the high levels of qualified support and customer service that we feel are essential to medical teams performing genomic analysis in clinical environments. Having a strong local partner in Portugal is key in our European expansion to make genomic testing available to all who need it.

The new distribution partnership signals SeqOne’s intention to capitalize on the fast-growing personalized medicine market in Portugal. 

As the Portuguese market embraces personalized medicine, the market for genomic analysis solutions is expanding rapidly. SeqOne’s high performance genomic analysis platform gives us the confidence that we can address the needs of the market and thus capitalize on this growth. We were impressed by SeqOne’s ability to support the full range of genomic analysis requirements, from simple analyses of small gene panels to the entire genome in both cancer and inherited diseases.  This means that we can offer a complete solution that addresses our customers’ needs.” said Cristina Iglésias da Costa CEO of ILC.

About SeqOne Genomics

SeqOne Genomics offers high-performance genomic analysis solutions for healthcare providers treating patients suffering from cancer, rare and hereditary diseases as well as pharmaceutical companies developing new therapies. The solution leverages advanced machine learning coupled with the company’s proprietary genomics operating system to dramatically reduce turnaround times and costs while delivering comprehensive and actionable insights for personalized medicine. The company has won numerous awards including the iLab award and the ARC cancer foundation’s Hélène Stark prize. Investors include Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes and Software Club. More information at: https://seqone.com

SeqOne Genomics media relations  

  • Annie-Florence Loyer – afloyer@newcap.fr / +33 (6) 88 20 35 59
  • Juliette Milleret – jmilleret@newcap.fr /+33 (6) 98 50 21 93

About ILC Instrumentos de Laboratório Científicos :

ILC has been in the Portuguese market since 1977 and has since been supporting the scientific community in the pursuit of knowledge and excellence. ILC has since partnered with some of the best companies in the world of Chemistry, Biology and Industry, in order to bring to Portugal the right technology and knowledge to allow its customers to reach their goals in the search of a better world.

SeqOne Genomics and Global Diagnostic Solutions Limited (GDS) extend their collaboration in MENA 

The companies will participate at the Precision Med Expo Dubai 24th and 25th of May 2022

Montpellier, France – Dubai, May 18, 2022 – SeqOne Genomics, provider of next genomic analysis solutions for personalized medicine and Global Diagnostic Solutions Ltd (GDS) today announced their participation in Precision Med Expo Dubai 24th and 25th of May at Conrad Dubai, booth A02.

Precision Medicine Expo has become a major catalyst in the development of personalized medicine in the MENA region. The decision to participate in the event is driven by the belief that huge advances in improving access to personalized medicine in the region can be made given the right solutions. The objective of the two partners at the event is to meet the geneticists, bioinformaticians, biopharma companies and researchers in the region to explore how SeqOne Genomics platform together with GDS support can accelerate the implementation of innovative new personalized medicine programs.  

The MENA region is increasingly committed to personalized medicine with a growing number of national and private sector initiatives,” said Nicolas Phillipe, CEO of SeqOne. “Having a strong local partner like GDS is essential in expanding our presence in the region through collaboration with local healthcare innovators to make genomic testing available to all who need it”.

We were impressed with SeqOne’s high-performance genomic analysis platform and are proud to represent them in the MENA market” Dr. Mohamed Ramadan, Regional Marketing Head of GDS. “We look forward to supporting local healthcare providers in delivering fast, accurate genomic tests that improve the accessibility of personalized medicine. We look forward to meeting you at Booth: A02.” 

About Precision Med Expo.

The Middle East’s Dedicated Precision Medicine Exhibition & Summit provides a vital opportunity for health tech and tech service providers to meet and do business and meet with key decision-makers in healthcare from across the Gulf / Middle East Region. Growing populations, rising life expectancy and changes in lifestyle are leaving a healthcare burden for governments in the Gulf region, they have an urgent need to find smart approaches to tackle the medical needs of their populations.

The Exhibition will take place at the Conrad Hotel Dubai on 24th and 25th of May 2022.

About SeqOne Genomics

SeqOne Genomics offers high-performance genomic analysis solutions for healthcare providers treating patients suffering from cancer, rare and hereditary diseases as well as pharmaceutical companies developing new therapies. The solution leverages advanced machine learning coupled with the company’s proprietary GeniOS™ genomics operating system to dramatically reduce turnaround times and costs while delivering comprehensive and actionable insights for personalized medicine. The company has won numerous awards including the iLab award and the ARC cancer foundation’s Hélène Stark prize. Investors include Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes and Software Club.  More information at: https://seqone.com

SeqOne Genomics media relations  

  • Annie-Florence Loyer – afloyer@newcap.fr / +33 (6) 88 20 35 59
  • Juliette Milleret – jmilleret@newcap.fr /+33 (6) 98 50 21 93

About Global diagnostic solutions Ltd.: 

A company with the objective of representing the Molecular Genetics of tomorrow, mapping today’s healthcare through personalized medicines and bioinformatics diagnostics tools with leading European diagnostic companies throughout the MENA Region. We communicate and represent the technology, leading the transformation.

Contact us: (https://gds-eg.com). You can reach us via email: info@gds-eg.com

SeqOne posters at the ESHG: using ML and big data to improve variant interpretation

ESHG 2022 - booth X4-664

SeqOne will be at the ESHG show in Vienna in hall X4 booth 664. We will be presenting four posters high-lighting various projects by SeqOne’s R&D team focussing on the use of Machine Learning and Big Data to better prioritize variants to improve accuracy and efficiency in interpreting genomic data. Stop by our booth to meet the authors and discuss your specific needs.


Automated prioritization of copy number variants with ACMG/ClinGen standards

Poster Presentation No.P18.056.D
Session No. & TitlePV04 – Poster Viewing with Authors (Group D)
Session Date & Time13/06/2022 15:45:00 – 13/06/2022 16:45:00 CEST
LocationPoster Hall X3
Authors
Jiri Ruzicka, Kévin Yauy, Nicolas Duforet-Frebourg, Laure Raymond, Mélanie Broutin, Jérôme Audoux, Sacha Beaumeunier, Nicolas Philippe, Denis Bertrand

Background: With the rising adoption of long-read sequencing technologies, previously undetected and numerous CNVs (Copy-number variants) are accessible and their prioritization becomes necessary for the clinical evaluation. ACMG and ClinGen published guidelines for clinical interpretation of such variations, which allow more consistent prioritization of CNVs.

Methods: We present an original implementation of the recommendations of the ACMG/ClinGen framework, adapted to both small and large CNVs. Classifications were processed using dosage map sensitivity, general population frequency, phenotype matching and disease inheritance patterns. The performance of the model was compared with the published ACMG/ClinGen dataset consisting of 114 CNVs evaluated by two independent experts.

Results: Our classification tool achieved 96.7% specificity for pathogenic variant identification, identifying correctly 15 of 23 CNV assessed as pathogenic by the two evaluators. 2 additional CNV could be classified as pathogenic when phenotypes were available. In 84.2% of CNVs, the prediction was the same as the prediction of at least one evaluator. For the 15.8% of predictions in disagreement, no variants classified as benign were predicted pathogenic and vice-versa.

Conclusion: This implementation of ACMG/ClinGen standards provides an automated and confident classification of CNVs which accelerates the clinical interpretation of structural variants.


Clinically-driven, multi-layered, and interpretable machine learning model for assisted variant interpretation

Poster Presentation No.P18.070.B
Session No. & TitlePV02 – Poster Viewing with Authors (Group B)
Session Date & Time12/06/2022 16:00:00 – 17:00:00 CEST
LocationPoster Hall X3
Authors
Jiri Ruzicka, Nicolas Duforet-Frebourg, Laure Raymond, Jérôme Audoux, Sacha Beaumeunier, Denis Bertrand, Laurent Mesnard, Nicolas Philippe, Julien Thevenon, Kévin Yauy 

Background: With the great expansion of sequencing technologies and artificial intelligence tools, the demand for interpretable classification of variants rises rapidly and highlights the need for a personalized approach based on the clinical context. Unfortunately, the low interpretability of machine learning black-box models limits their adoption in the community.  

Methods: We created a multi-layered machine learning model called ClassifyML which scores the pathogenicity of genomic variants and prioritizes their importance for the clinical context. ClassifyML gathers multi-level annotations based on ACMG-AMP evidence criteria, disease heritability patterns, and phenotype matching. The model was trained firstly on the ClinVar variant classification dataset, followed by a second training on a cohort of 316 deep-phenotyped patients recruited from a French consortium. 

Results: The model proposes an interpretable output in the form of a continuous importance scale for each criterion, which assists the clinical interpretation of variants. We evaluated our method with a multi-centric cohort consisting of 310 patients. The causing variant was classified as having pathogenic evidence in 291 of 310 cases by the model, with an improvement of the median rank of 39 fold compared to Exomiser (3 against 118).

Conclusion: ClassifyML is an interpretable machine learning model for pathogenicity prediction and variant prioritization. It allows variant classification prediction, patient context integration, and yields human-explainable classifications.


A phenotype-gene based graph for symptoms description harmonization and clinically-driven genomic analysis 

Poster Presentation No.P18.011.C
Session No. & TitlePV03 – Poster Viewing with Authors (Group C)
Session Date & Time13/06/2022 12:45:00 – 13:45:00 CEST
Location:Poster Hall X3
Authors
Kévin Yauy, Nicolas Duforet-Frebourg, Jérôme Audoux, Sacha Beaumeunier, Denis Bertrand, Laurent Mesnard, Nicolas Philippe, Julien Thevenon

Background: Identical symptoms observed in patients may heterogeneously be described by physicians, even though relying on the same Human Phenotype Ontology (HPO). Several tools explore the accuracy of generating diagnostic hypotheses based on HPO terms associations and vicinity in the ontology, although bearing common methodological limitations.

Methods: We build a phenotype-gene graph weighted by consensus of associations identified on both structured and free-text databases extracted by ElasticSearch. To manage the diversity of physicians’ descriptions, dimensionality reduction of HPO terms was obtained through Non-Negative Matrix Factorization. Based on this graph, we developed a phenotype-gene matching algorithm called PhenoGenius. We evaluated our approach on a multicentric cohort of 316 patients recruited from a French consortium and 444 patients from literature. 

Results: The graph presents more than 2 million phenotype-gene associations, covering 4,974 genes and 9,687 symptoms, whereas the Monarch database contains nearly 640,000 associations. PhenoGenius performance allows a median diagnostic gene rank of 68 (whereas others algorithms range from 144-355). Reducing 9,687 symptoms into 650 groups leads to the reduction of the diagnostic rank dispersion (reducing the standard deviation of 48%) without compromising the ranking performances. Focusing on 650 groups achieve complete coverage of the medical observations and expanded matchings to every medical observation, gaining 24 diagnostics. 

Conclusion: This work explored a weighted phenotype-gene association graph, dissociated from the HPO developmental-based hierarchy used to describe patients’ phenotypes. PhenoGenius presents an original method that harmonizes and maximizes the usage of clinical symptoms in bioinformatic processes, outperforming currently published approaches. 


Automated identification of a cancer patient treatment: from sequencing to treatment prioritisation

Poster Presentation No.P19.020.C
Session No & TitlePV03 – Poster Viewing with Authors (Group C)
Session Date & Time13/06/2022 12:45:00 – 13:45:00 CEST
LocationPoster Hall X3
Authors
Nicolas Soirat, Denis Bertrand, Sacha Beaumeunier, Nicolas Philippe, Dominique Vaur, Sophie Krieger, Anne-Laure Bougé, Laurent Castera

Background/Objectives: The emergence of sequencing allowed the scientific community to gather a tremendous amount of cancer genomic data, characterising biomarkers responsible for tumorigenesis that might indicate potential treatments. The use of short-read sequencing to identify cancer patient treatment is becoming a more common practice in hospitals. To standardise the treatment identification some  prediction frameworks have been developed, but they mostly focus on a single alteration type and very few have been implemented.

Methods: We design a targeted DNA and RNA panel covering 639 cancer genes and 57 fusion genes to obtain a comprehensive patient genomic landscape. We developed a decisional algorithm which prioritises all known variant-therapy associations. Several rules give a score for each association based on more than 20 variant features indicating the variant impact in cancer, the patient indication and similarity of patient variant with variant in therapeutic databases.

Result: We generated a thousand simulated tumours, each containing passenger mutations and a targetable mutation from the Civic database. Our method correctly classifies the targetable mutation in its top predictions (average rank 2.19). Furthermore, on a cohort of 12 patients, we obtain similar results as 2 clinical routine approaches using our fully automated protocol. Currently, we are expanding our validation to a pan-cancer cohort of 500 patients.

Conclusion: We design a complete framework for multiple variant drug association identification in order to make easier therapeutic choices for a clinician. We succeed to integrate it into our variant calling workflow and show good performance of our method to prioritise targetable variants.

SFMPP 2021

SeqOne participe au congrès annuel organisé par la SFMPP – Société Française de Médecine Prédictive et Personnalisée qui aura lieu du 29 Septembre au 1er Octobre 2021 à l’Institut des Cordeliers à Paris.

Pour cette édition, SeqOne organise un déjeuner-débat le Jeudi 30 Septembre à 12h45 sur le thème “RCP moléculaire : comment intégrer les données génomiques et l’IA dans le parcours de soin des patients”

Le Dr Benoist Chibaudel, Oncologue médical à l’Hôpital Franco-Britannique et le Dr Daniel Toledano, Généticien à l’Institut Rafaël et à l’Institut Français du Sein partageront leurs expériences sur l’utilisation du profilage moléculaire pour mieux personnaliser les traitements et la prévention

Ce retour d’expérience sera suivi d’un débat animé par le Dr Cyril Sarrauste de Menthiere autour de l’importance de l’interprétation des données et de leur partage, la place de l’IA avec un éclairage juridique sur l’accès et l’utilisation des données génomiques.

Participeront à ce débat : le Dr Jérémie Mortreux (Biomnis), le Dr Etienne Muller (Cerba), Me Carole Henry (Phase 4 avocat), Leslie (utilisatrice de Mon Réseau Cancer Poumon) et le Dr Philippe (SeqOne).

Retrouvez nous également sur notre stand 4 et venez partager un moment de convivialité le mercredi 29 Septembre à 19h autour de notre cocktail de Bienvenue.

ESHG 2021 Conference – Satellite symposium replay

With @Eurofins Biomnis, SeqOne recently held a symposium on CNV detection in exome data, performance comparisons with traditional method and the clinical impact of fast reliable exome CNV detection.

SHORTCUT TO THE TALKS OF THE SESSION:

1:27 Prof. Laurent Mesnard, PhD in Physiopathology, MD Nephrologist, Hospital Tenon/Sorbonne University exploring  the clinical impact of fast reliable exome CNV results in adult nephrology,

15:36 Laure Raymond, Geneticist, Eurofins / Biomnis, discussing challenges involved in interpreting exome CNV and performance compared to traditional approaches,

29:48 Samantha Brunel, PhD in Molecular Biology, SeqOne Genomics product expert presenting  implementation exome CNV analysis in clinical routine.  

39:57 Q&A session

Would you like to test our exome CNV solution or know more about it?

Contact us today at sales@seqone.com